TY - JOUR
T1 - αv integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma
AU - Goldberg, Iris
AU - Kopolovic, Juri
AU - Gotlieb, Walter H.
AU - Ben-Baruch, Gilad
AU - Davidson, Ben
AU - Berner, Aasmund
AU - Nesland, Jahn M.
AU - Bryne, Magne
AU - Reich, Reuven
PY - 2001
Y1 - 2001
N2 - Purpose: To analyze the possible correlation between expression of the αv and β1 integrin chains and survival in advanced-stage ovarian carcinomas, studying two patient groups with extremely different disease outcome. Experimental design: Sections from 56 primary ovarian carcinomas and metastatic lesions from 34 patients diagnosed with advanced-stage ovarian carcinoma (Fédération Internationale des Gynaecologistes et Obstetristes stages III-IV), divided into long-term (16) and short-term (18) survivors, were evaluated for expression of αv and β1 integrin chains using mRNA in situ hybridization. Protein expression was additionally studied in 52 specimens using immunohistochemistry. Results: The mean values for disease-free survival and overall survival were 115 and 132 months for long-term survivors, as compared with 4 and 23 months for short-term survivors, respectively. Expression of αv integrin mRNA was observed in carcinoma (18 of 56; 32%) and stromal (17 of 56; 30%) cells. β1 integrin mRNA was similarly detected in carcinoma (25 of 56; 47%) and stromal (19 of 56; 34%) cells. No significant differences were observed when primary and metastatic lesions were compared (P > 0.05). αv integrin mRNA was present more often in carcinoma cells in tumors of short-term survivors (P = 0.017 for carcinoma cells). In univariate survival analysis for all cases, αv integrin mRNA expression in tumor cells correlated with poor survival (P = 0.012). This finding retained its predictive power in a multivariate survival analysis, in which all of the molecules studied previously in this patient cohort were included (P = 0.031). Immunohistochemistry confirmed the differences in αv integrin expression in tumor cells of short-term as compared with long-term survivors, whereas β1 integrin protein expression was comparable in the two groups. Conclusions: To our best knowledge, this is the first evidence associating integrin expression with poor survival in ovarian carcinoma. αv integrin is, thus, a novel prognostic marker in advanced-stage ovarian carcinoma.
AB - Purpose: To analyze the possible correlation between expression of the αv and β1 integrin chains and survival in advanced-stage ovarian carcinomas, studying two patient groups with extremely different disease outcome. Experimental design: Sections from 56 primary ovarian carcinomas and metastatic lesions from 34 patients diagnosed with advanced-stage ovarian carcinoma (Fédération Internationale des Gynaecologistes et Obstetristes stages III-IV), divided into long-term (16) and short-term (18) survivors, were evaluated for expression of αv and β1 integrin chains using mRNA in situ hybridization. Protein expression was additionally studied in 52 specimens using immunohistochemistry. Results: The mean values for disease-free survival and overall survival were 115 and 132 months for long-term survivors, as compared with 4 and 23 months for short-term survivors, respectively. Expression of αv integrin mRNA was observed in carcinoma (18 of 56; 32%) and stromal (17 of 56; 30%) cells. β1 integrin mRNA was similarly detected in carcinoma (25 of 56; 47%) and stromal (19 of 56; 34%) cells. No significant differences were observed when primary and metastatic lesions were compared (P > 0.05). αv integrin mRNA was present more often in carcinoma cells in tumors of short-term survivors (P = 0.017 for carcinoma cells). In univariate survival analysis for all cases, αv integrin mRNA expression in tumor cells correlated with poor survival (P = 0.012). This finding retained its predictive power in a multivariate survival analysis, in which all of the molecules studied previously in this patient cohort were included (P = 0.031). Immunohistochemistry confirmed the differences in αv integrin expression in tumor cells of short-term as compared with long-term survivors, whereas β1 integrin protein expression was comparable in the two groups. Conclusions: To our best knowledge, this is the first evidence associating integrin expression with poor survival in ovarian carcinoma. αv integrin is, thus, a novel prognostic marker in advanced-stage ovarian carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=0035542949&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 11751504
AN - SCOPUS:0035542949
SN - 1078-0432
VL - 7
SP - 4073
EP - 4079
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 12
ER -
